Determine the necessary mass, volume, or concentration for preparing a solution.
MLN3126 - ≥98% , CAS No.628300-71-0
AVAILABLE TO ORDER
GRADE & PURITY ≥98%
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
224,000+ research products · Triple ISO certified · COA & SDS available for every product · Same-day shipping on in-stock items
Why this grade
≥98% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Overview
MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC 50 value of 6.3 nM for calcium influx.
In Vitro
MLN3126 inhibits CCL25-induced calcium mobilization with an IC 50 value of 6.3 nM in CCR9 expressing cells. MLN3126 inhibits the binding of biotinylated CCL25 to CCR9 with an IC 50 of 14.2 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Invasion AssayCell Line: Mouse thymocytes Concentration: 0.01, 0.03, 0.1, 0.3, 1, 3 μM Incubation Time: 90 min Result: Inhibited CCL25-induced chemotaxis of mouse thymocytes.
In Vivo
MLN3126 (2.5% w/w; p.o.) decreases colonic level of IFN-γ, largely produced by T cells . MLN3126 (0.05, 0.25 and 1% (w/w); p.o.) has the potential activity for alleviating inflammatory bowel disease (IBD) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Activated T cell transferred colitis mouse model Dosage: 0.05, 0.25 and 1% (w/w) (around 4 g/day) Administration: Oral gavage; 21 days Result: Blocked CCR9/CCL25 interaction by inhibiting migration of T cells to the colon and resulted in the amelioration of colitis.
Form:Solid
Specifications
Specifications & Purity
≥98%
Biochemical and Physiological Mechanisms
MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC 50 value of 6.3 nM for calcium influx.
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
ANTAGONIST
Purity
≥98%
Names and Identifiers
| Molecular Weight | 446.90 |
|---|
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificates（CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemical and Physical Properties
| Solubility | DMSO : 25 mg/mL (55.94 mM; ultrasonic and warming and heat to 60°C) |
|---|
Solution Calculators
Reviews
Customer Reviews
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.